148 related articles for article (PubMed ID: 7692455)
21. Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by up-regulation of hepatocyte growth factor.
Makino H; Aoki M; Hashiya N; Yamasaki K; Hiraoka K; Shimizu H; Azuma J; Kurinami H; Ogihara T; Morishita R
Hypertens Res; 2004 Feb; 27(2):85-91. PubMed ID: 15005271
[TBL] [Abstract][Full Text] [Related]
22. Endothelial function in patients with peripheral vascular disease: influence of prostaglandin E1.
Weiss T; Fischer D; Hausmann D; Weiss C
Prostaglandins Leukot Essent Fatty Acids; 2002 Nov; 67(5):277-81. PubMed ID: 12445486
[TBL] [Abstract][Full Text] [Related]
23. Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease.
Gianetti J; De Caterina M; De Cristofaro T; Ungaro B; Guercio RD; De Caterina R
Am Heart J; 2001 Oct; 142(4):733-9. PubMed ID: 11579367
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases].
Bucci M; Iacobitti P; Laurora G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439
[TBL] [Abstract][Full Text] [Related]
25. [Tolerance and therapeutic results of iloprost in obliterative arteriopathy in lower limbs at the severe chronic ischemia stage. A retrospective study of 29 consecutive cases].
Duthois S; Cailleux N; Lévesque H
J Mal Vasc; 2000 Feb; 25(1):17-26. PubMed ID: 10705132
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease.
Hildebrand M; Krause W; Oberender HA; Zurdel-Dillinger S; Jünger M; Bodenburg H
Eicosanoids; 1990; 3(3):145-8. PubMed ID: 1700723
[TBL] [Abstract][Full Text] [Related]
27. [Prostacyclin (iloprost) as an adjuvant in local surgical therapy of stage IV arterial occlusive disease--is quantification of the therapeutic effect possible with tcPO2 measurements?].
Breuer C; Abri O
Vasa; 1995; 24(1):62-71. PubMed ID: 7536999
[TBL] [Abstract][Full Text] [Related]
28. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
Böger RH; Bode-Böger SM; Thiele W; Creutzig A; Alexander K; Frölich JC
J Am Coll Cardiol; 1998 Nov; 32(5):1336-44. PubMed ID: 9809945
[TBL] [Abstract][Full Text] [Related]
29. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study.
Trübestein G; von Bary S; Breddin K; Diehm C; Gruss JD; Heinrich H; Horsch S; Kriessmann A; Maass U; Martin M
Vasa Suppl; 1989; 28():44-9. PubMed ID: 2692200
[TBL] [Abstract][Full Text] [Related]
30. Prospects of prostanoid therapy. Preliminary results.
Castagno PL; Di Molfetta L; Merlo M; Barile G; Violato F; Buzzacchino A; Ponzio F
Minerva Cardioangiol; 2000; 48(1-2):9-18. PubMed ID: 10829583
[TBL] [Abstract][Full Text] [Related]
31. Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease.
Trifiletti A; Scamardi R; Pizzoleo MA; Sottilotta G; Soraci S; Attinà A; Bagnato L; Barbera N
Panminerva Med; 1999 Mar; 41(1):15-7. PubMed ID: 10230250
[TBL] [Abstract][Full Text] [Related]
32. Study of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapy.
Trifiletti A; Bartolone S; Scamardi R; Pizzoleo MA; Attinà A; Sottilotta G; Canobbio V; Soraci S; Barbera N
Minerva Cardioangiol; 1999 Mar; 47(3):55-8. PubMed ID: 10389444
[TBL] [Abstract][Full Text] [Related]
33. [Prostaglandin E1 in stage III and IV arterial occlusive diseases. results of a multicenter study].
Trübestein G; Ludwig M; Diehm C; Gruss JD; Horsch S
Dtsch Med Wochenschr; 1987 Jun; 112(24):955-9. PubMed ID: 3297596
[TBL] [Abstract][Full Text] [Related]
34. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
[TBL] [Abstract][Full Text] [Related]
35. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial.
Mlekusch W; Schillinger M; Sabeti S; Al-Awami M; Gschwandtner M; Minar E
Vasa; 2004 Aug; 33(3):131-6. PubMed ID: 15461064
[TBL] [Abstract][Full Text] [Related]
36. [Continuous intra-arterial perfusion of prostaglandin E1 in inoperable stage-IV arteriopathies].
Gruss JD; Bartels D; Haidar A; Vargas H; Simmenroth H
J Mal Vasc; 1983; 8(2):133-7. PubMed ID: 6683740
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of a novel method of intravenous infusion of the prostaglandin analogue iloprost for the treatment of lower-limb critical ischemia: An open-label, nonrandomized study in two cohorts.
Veroux P; Veroux M; Macarone M; Bonanno MG; Tumminelli MG
Curr Ther Res Clin Exp; 2004 May; 65(3):255-65. PubMed ID: 24672081
[TBL] [Abstract][Full Text] [Related]
38. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery].
MMW Fortschr Med; 2003 Dec; 145(51-52):41. PubMed ID: 14974333
[No Abstract] [Full Text] [Related]
39. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.
Brass EP; Anthony R; Dormandy J; Hiatt WR; Jiao J; Nakanishi A; McNamara T; Nehler M;
J Vasc Surg; 2006 Apr; 43(4):752-9. PubMed ID: 16616232
[TBL] [Abstract][Full Text] [Related]
40. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
Weiss T; Griesshaber J; Rogatti W; Kistner O; Hsu E; Jansen T; Diehm C
Vasa Suppl; 1991; 33():341-2. PubMed ID: 1788749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
